General Information of Drug Metabolite (DM) (ID: DM001016)
DM Name
Retinoic acid
Synonyms
Retinoic acid|tretinoin|302-79-4|all-trans-Retinoic acid|Vitamin A acid|trans-Retinoic acid|ATRA|Retin-A|Aberel|Eudyna|Renova|Vesanoid|Airol|All-trans Retinoic Acid|Dermairol|Aknoten|all-trans-Vitamin A acid|Aknefug|Cordes vas|Epi-aberel|Tretin M|Atralin|all-trans-Tretinoin|Retionic acid|all-trans-Vitamin A1 acid|All Trans Retinoic Acid|TRETINON|Retin A|Retin-A Micro|Vitamin A1 acid, all-trans-|beta-Retinoic acid|Effederm|all-(E)-Retinoic acid|Vitamin A acid, all-trans-|(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid|beta-Ra|Alltrans-retinoic acid|Retinoic acid, all-trans-|Betarretin|Tretinoina|Tretinoine|Tretinoino|Tretinoinum|Aberela|Acnavit|Avitoin|NSC-122758|A-Vitaminsyre|A-Acido (Argentina)|Stieva-A|all trans-Retinoic acid|Ro 1-5488|Aberela [Norway]|Avitoin [Norway]|Acnavit [Denmark]|Effederm [France]|Retinoate|Kerlocal|Refissa|Retacnyl|Vesnaroid|Oristar rna|all-trans-beta-Retinoic acid|Tretinoin, all-trans-|Acid, Retinoic|Cordes VAS [Germany]|Retisol-A|Vitamin a acid, trans-|A-Vitaminsyre [Denmark]|Acid, Vitamin A|Tretinoine [INN-French]|Tretinoinum [INN-Latin]|Tretinoina [INN-Spanish]|Tretinoino [INN-Spanish]|trans Retinoic Acid|15-Apo-beta-caroten-15-oic acid|Acid, trans-Retinoic|Acid A Vit (Belgium, Netherlands)|.beta.-Retinoic acid|CCRIS 3294|Nexret|DTXSID7021239|RETINOIC ACID, ALL TRANS|HSDB 2169|Acid, all-trans-Retinoic|Tretinoin/All-Trans Retinoic Acid|Avita Gel|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|tretinoin liposome|(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|EINECS 206-129-0|beta-all-trans-Retinoic acid|Tretinoin [USAN:INN:BAN]|[3H]Retinoic acid|NSC 122758|UNII-5688UTC01R|Renova (TN)|ALTRENO|BRN 2057223|(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid|2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-|Avita (TN)|MLS000028588|b-Retinoic acid|CHEBI:15367|Retinoic acid (GMP)|5688UTC01R|AT-RA|CHEMBL38|11-cis,13-cis-|NSC122758|all-trans-b-Retinoic acid|AGN 100335|Renova (0.02% cream)|Altreno (0.05% lotion)|Tretinoin (JAN/USP/INN)|Avita (0.025% gel)|Atragen|Retinova|SMR000058245|tretinoin sodium|BML2-E05|DTXCID001239|tretinoine (French) (EINECS)|ZIANA COMPONENT TRETINOIN|all-trans-retinoic acid (ATRA)|SOLAGE COMPONENT TRETINOIN|TWYNEO COMPONENT TRETINOIN|VELTIN COMPONENT TRETINOIN|Tretinoin 0.1% cream or placebo|Acide retinoique (French) (DSL)|Tretinoin [USAN:USP:INN:BAN]|tretinoin potassium|Aberela (Norway)|Avitoin (Norway)|Tretinoin (TN)|Acnavit (Denmark)|Effederm (France)|TRETINOIN COMPONENT OF ZIANA|TRI-LUMA COMPONENT TRETINOIN|TRETINOIN COMPONENT OF SOLAGE|TRETINOIN COMPONENT OF TWYNEO|TRETINOIN COMPONENT OF VELTIN|Tretinoin Zinc Salt|(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid|3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid|TRETINOIN COMPONENT OF TRI-LUMA|Salt, Tretinoin Zinc|Zinc Salt, Tretinoin|PDT-002-002|9-cis-RA|Retin A (TN)|NCGC00017280-10|Cordes VAS (Germany)|A-Vitaminsyre (Denmark)|MFCD00001551|TRETINOIN (MART.)|TRETINOIN [MART.]|R 2625|TRETINOIN (USP-RS)|TRETINOIN [USP-RS]|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)|3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid|Lsotretinoin|Vitinoin|trans-Retinoate|beta-Retinoate|Accutane Roche|Stieva-a Forte|TRETINOIN (EP MONOGRAPH)|TRETINOIN [EP MONOGRAPH]|cis-Retinoic acid|TRETINOIN (USP MONOGRAPH)|TRETINOIN [USP MONOGRAPH]|Trans-Retinoicacid|Atra-IV|Vesanoid (TN)|Retinoic acid, cis-|LGD 100057|3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid|(11Z)-retinoic acid|Isotretinoin;(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid|ISOTRETINOIN IMPURITY A (EP IMPURITY)|ISOTRETINOIN IMPURITY A [EP IMPURITY]|Tretinoin Sodium Salt|Salt, Tretinoin Sodium|Sodium Salt, Tretinoin|SR-01000000239|Tretinoin Potassium Salt|Tretinoin [USAN:BAN:INN]|Potassium Salt, Tretinoin|Salt, Tretinoin Potassium|BAL4079|retinoicacid|beta all trans Retinoic Acid|Tretinion|Biacna|Acid, beta-all-trans-Retinoic|TNP00194|Acide retinoique|1cbr|[3H]tretinoin|[All-E]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|CAS-302-79-4|Tretinoin; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; Retinoic acid; Isotretinoin Impurity A|Prestwick_424|Aberela (TN)|all-(E)-Retinoate|Tretinoine (French)|Stieva-A (TN)|(5E)-Retinoic acid|9-trans-retinoic acid|[3H]Vitamin A acid|Retin-A (TN)|RETIN-A-MICRO|1n4h|CPD000058245|Retinoic acid all trans|3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid|TRETINOIN [INN]|TRETINOIN [JAN]|Isotretinoin Retinoicacid|6-s-trans-retinoic acid|NONATETRANOIC ACID|TRETINOIN [HSDB]|TRETINOIN [USAN]|Vitamin-A-sA currencyure|Opera_ID_1055|Prestwick2_000257|Prestwick3_000257|Spectrum5_001746|Spectrum5_001933|TRETINOIN [VANDF]|acide retinoique (French)|Vesanoid (TN) (Roche)|bmse000562|D02DGU|D0A8ND|UPCMLD-DP097|RETINOIC ACID [MI]|SCHEMBL3145|TRETINOIN [WHO-DD]|(9Z,13Z)-Retinoic acid|BIDD:PXR0081|Lopac0_001061|BSPBio_000074|BSPBio_001500|RETINOIC ACID [INCI]|MLS001076515|MLS002207234|MLS002222211|MLS002548861|MLS006010222|BIDD:GT0483|SPECTRUM1502016|9-cis-retinoic acid (9cRA)|LGD 1057; NSC 659772; Panretin; Panretyn; Panrexin; Toctino|[3H]RA|BPBio1_000082|cid_444795|GTPL2644|.beta.-all-trans-Retinoic acid|TRETINOIN [ORANGE BOOK]|SCHEMBL19091395|BDBM31883|HMS502N05|D10AD01|L01XX14|Retinoic acid, all-trans-(8CI)|BCPP000036|BDBM323588|HMS1361K22|HMS1568D16|HMS1791K22|HMS1921D14|HMS1989K22|HMS2089D20|HMS2092N11|HMS2095D16|HMS2236N03|HMS3259E11|HMS3263E04|HMS3402K22|HMS3411B09|HMS3675B09|HMS3712D16|Pharmakon1600-01502016|Retinoic acid, all-trans- (8CI)|124510-04-9|97950-17-9|BCP01405|DRG-0147|US10188615, at-RA|ALL TRANS-BETA-RETINOIC ACID|Tox21_110812|Tox21_202330|Tox21_300305|Tox21_501061|AGN100335|All-trans Retinoic Acid (Tretinoin)|CCG-39912|HY-14649G|LMPR01090019|NSC759631|s1653|AKOS000280845|Tox21_110812_1|AC-6824|CS-1269|DB00755|GS-3578|LP01061|LS-1154|NC00481|NSC-759631|SDCCGSBI-0051031.P004|IDI1_000903|IDI1_033970|NCGC00017280-05|NCGC00017280-06|NCGC00017280-07|NCGC00017280-08|NCGC00017280-09|NCGC00017280-12|NCGC00017280-15|NCGC00017280-16|NCGC00017280-17|NCGC00017280-18|NCGC00017280-19|NCGC00017280-20|NCGC00017280-23|NCGC00017280-38|NCGC00021808-04|NCGC00021808-05|NCGC00021808-06|NCGC00021808-07|NCGC00021808-09|NCGC00021808-11|NCGC00021808-14|NCGC00021808-15|NCGC00254179-01|NCGC00259879-01|NCGC00261746-01|BP-20401|BR164493|HY-14649|Retinoic acid, >=98% (HPLC), powder|SBI-0051031.P003|CS-0626116|EU-0101061|R0064|SW203749-4|C00777|D00094|Q29417|AB00052318-15|AB00052318-16|AB00052318-17|AB00052318_18|AB00052318_19|A899883|EN300-27107561|L000833|Q-200610|SR-01000000239-3|SR-01000000239-4|SR-01000000239-6|SR-01000000239-7|BRD-K06926592-001-01-7|BRD-K71879491-001-15-0|BRD-K71879491-001-22-6|SR-01000000239-12|SR-01000000239-13|SR-01000000239-14|SR-01000000239-15|WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1|Tretinoin, European Pharmacopoeia (EP) Reference Standard|WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1|Tretinoin, United States Pharmacopeia (USP) Reference Standard|Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin|3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-|Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material|(2E,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid|(4E,6E,8E)-9-(2,6,6-Trimethyl-1-cyclohexenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid|(8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid|(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate|2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-|2,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-|3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-XL-2,4,6,8-NONATETRAENOIC ACID|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate|3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRANOIC ACID|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6E,8E,-nonatetraenoic acid|all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid|(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid|2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)-|2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)-|2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)-|2,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)-
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 300.4 Topological Polar Surface Area 37.3
Heavy Atom Count 22 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
PubChem CID
444795
Complexity
567
Formula
C20H28O2
Canonical SMILES
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C
InChI
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
InChIKey
SHGAZHPCJJPHSC-YCNIQYBTSA-N
IUPAC name
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
Toxicity Properties of This DM
Documented Toxicity Properties
Toxicity Class Toxic PMID: 11757674
Predicted Toxicity Properties
Physical and chemical properties LogP

The log of the n-octanol/water distribution coefficient.

LogP possess a leading position with considerable impact on both membrane permeability and hydrophobic binding to macromolecules. Therefore, LogP is widely used in drug discovery and development as an indicator of potential utility of a solute as a drug.

The predicted logP of a compound in the range from 0 to 3 log mol/L will be considered proper.

5.109 TPSA

Topological polar surface area

In TPSA, PSA is estimated only from the syntype (topology) of atoms in the molecule, without considering the three-dimensional structure of the molecule, which is the origin of the name topological polar surface area.

The TPSA of a compound in the range from 0 to 140 will be considered proper, based on Veber rule.

37.3
Pfizer Rule: Rejected

Molecules with a high log P (>3) and low TPSA (<75) are likely to be toxic.

Pfizer infered the relationship between the physicochemical properties and toxicity of the drug from an animal tolerability (IVT) study dataset of 245 preclinical Pfizer compounds.Compounds with a high log P (>3) and low TPSA ( <75) are likely to be toxic.

(Bioorg Med Chem Lett. 18(17):4872-5. 2008)

Structural Characteristics ALARM NMR Rule

Molecules containing the reactivity-related thiol substructures are likely to be toxic.

The high-throughput screening (HTS) hit rate of reactive compounds was evaluated by NMR screening, X-ray crystallography and other biochemical and biophysical experiments, and then 75 thiol substructures for predicting reactivity were obtained by computational means for 2348 screening hit reactive compounds and 1156 reactive compounds obtained by La protein experiments.The molecule was matched to 75 reactivity-related substructures to obtain the information how many alarm groups the molecule contained and determine whether it was a thiol-reactive compound. Molecules with the thiol substructures are likely to be toxic.

(J Am Chem Soc. 127(1):217-24. 2005)

0 PAINS

Molecules containing the reactive substructures are likely to be toxic.

Pan Assay Interference Compounds (PAINS) is one of the most famous frequent hitters filters, which comprises 480 substructures derived from the analysis of FHs determined by six target-based HTS assay. By application of these filters, it is easier to screen false positive hits and to flag suspicious compounds in screening databases. One of the most authoritative medicine magazines Journal of Medicinal Chemistry even requires authors to provide the screening results with the PAINS alerts of active compounds when submitting manuscripts.

(J Med Chem. 45(1):137-42. 2002)

0
BMS Rule

Molecules containing the reactivity-related substructures are likely to be toxic.

BMS's primary HTS data over the past 12 years was evaluated and analyzed to determine the correlation of a group of compound functional groups with Promiscuity, defined as a drug that acts with multiple molecular targets and exhibits different pharmacological effects.

(J Chem Inf Model. 46(3):1060-8. 2006)

1 Chelator Rule

Molecules containing the substructures associated with metalloprotease targeting are likely to be toxic.

The chelate substructure fragment library (eCFL) for targeting metalloproteinases was prepared and its effectiveness in screening metalloproteinase inhibitors was verified by analysis and fluorescence-based assay experiments, and 55 substructures associated with metalloprotease targeting were finally determined as alert structures.

(ChemMedChem. 5(2):195-9. 2010)

0
Genotoxic Carcinogenicity Rule

Molecules containing the Genotoxic substructures are likely to be carcinogenic.

By constructing a molecular structure dataset containing the corresponding Ames test data (mutagens and non-mutagens). The substructure of the dataset is searched, and then the toxic substructure obtained by using chemical and mechanical knowledge and statistical criteria is derived, and the new toxic substructure is obtained and approved, and finally the reliability of the verification set is verified. Molecules containing these substructures may cause carcinogenicity or mutagenicity through genotoxic mechanisms.There are 117 substructures in this endpoint.

(J Med Chem. 48(1):312-20. 2005)

0 Non-genotoxic Carcinogenicity Rule

Molecules containing the NonGenotoxic substructures are likely to be carcinogenic.

Through the analysis and verification of the existing molecular library or the molecular library mined by data, the list of non-gene carcinogenic substructures (SA) is obtained according to the computerized data mining analysis, and finally the reliability of the substructure is verified. Molecules containing these substructures may cause carcinogenicity through nongenotoxic mechanisms. There are 23 substructures in this endpoint.

(Mutat Res. 659(3):248-61. 2008)

1
Toxicity Model Prediction hERG Blockers

The possibility of causing cardiotoxicity.

The human ether-a-go-go related gene. The During cardiac depolarization and repolarization, a voltage-gated potassium channel encoded by hERG plays a major role in the regulation of the exchange of cardiac action potential and resting potential. The hERG blockade may cause long QT syndrome (LQTS), arrhythmia, and Torsade de Pointes (TdP), which lead to palpitations, fainting, or even sudden death.So build a model by collecting a dataset to predict whether a compound is a hERG Blocker.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.087 (---) H-HT

The possibility of causing .hepatotoxicity.

The human hepatotoxicity. Drug induced liver injury is of great concern for patient safety and a major cause for drug withdrawal from the market. Adverse hepatic effects in clinical trials often lead to a late and costly termination of drug development programs.So build a model by collecting datasets to predict whether compounds will cause hepatotoxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.879 (++)
DILI

The possibility of causing liver injury.

Drug-induced liver injury (DILI) has become the most common safety problem of drug withdrawal from the market over the past 50 years.So build a model by collecting datasets to predict whether compounds will cause liver injury.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.046 (---) CAMES Toxicity

The possibility of causing mutagenicity.

The Ames test for mutagenicity. The mutagenic effect has a close relationship with the carcinogenicity, and it is the most widely used assay for testing the mutagenicity of compounds.So build a model by collecting datasets to predict whether compounds will cause mutagenicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.097 (---)
Carcinogencity

The possibility of causing Carcinogencity.

Among various toxicological endpoints of chemical substances, carcinogenicity is of great concern because of its serious effects on human health. The carcinogenic mechanism of chemicals may be due to their ability to damage the genome or disrupt cellular metabolic processes. Many approved drugs have been identified as carcinogens in humans or animals and have been withdrawn from the market.So build a model by collecting datasets to predict whether compounds will cause Carcinogencity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.514 (+) Respiratory Toxicity

The possibility of causing Respiratory Toxicity.

Among these safety issues, respiratory toxicity has become the main cause of drug withdrawal. Drug-induced respiratory toxicity is usually underdiagnosed because it may not have distinct early signs or symptoms in common medications and can occur with significant morbidity and mortality.Therefore, careful surveillance and treatment of respiratory toxicity is of great importance.So build a model by collecting datasets to predict whether compounds will cause Respiratory Toxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.949 (+++)
Full List of Drug-Metabolizing Enzyme (DME) Related to This DM
DME(s) Producing This DM through Metabolism
DME Name DME ID Reactant Reaction Related Drug REF
Aldehyde dehydrogenase 1 (ALDH1) DME0286 Unclear - Unclear Beta carotene [1]
Aldehyde dehydrogenase family 1 member A3 (ALDH1A3) DMEN146 Unclear - Unclear Beta carotene [1]
cellular-retinoic acid binding protein 1 (CRAPB1) DMEN402 Unclear - Unclear Beta carotene [1]
cellular-retinoic acid binding protein 2 (CRAPB2) DMEN403 Unclear - Unclear Beta carotene [1]
Cytochrome P450 3A4 (CYP3A4) DME0001 Unclear - Unclear Isotretinoin [2] , [3] , [4] , [5]
Retinal dehydrogenase 2 (ALDH1A2) DME0287 Unclear - Unclear Beta carotene [1]
DME(s) Metabolizing This DM
DME Name DME ID Product Reaction Related Drug REF
Cytochrome P450 26C1 (CYP26C1) DME0600 Unclear - Unclear Beta carotene [1]
Retinoic acid 4-hydroxylase 26A1 (CYP26A1) DME0227 Unclear - Unclear Beta carotene [1]
Retinoic acid 4-hydroxylase 26B1 (CYP26B1) DME0032 Unclear - Unclear Beta carotene [1]
Sphingolipid delta(4)-desaturase DES1 (DES1) DMEN387 Unclear - Unclear Beta carotene [1]
Full List of Drug(s) That Produce This DM By Metabolism
Beta carotene DR0204 Approved Vitamin deficiency
Alitretinoin DR2501 Approved Kaposi sarcoma
Isotretinoin DR0890 Approved Acne vulgaris
References
1 #NAME?
2 Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity Xenobiotica. 1990 Feb;20(2):193-207. doi: 10.3109/00498259009047155.
3 Isotretinoin and its Metabolites Alter mRNA of Multiple Enzyme and Transporter Genes In Vitro, but Downregulation of Organic Anion Transporting Polypeptide Does Not Translate to the Clinic Drug Metab Dispos. 2022 Jul;50(7):1042-1052. doi: 10.1124/dmd.122.000882.
4 The use of isotretinoin in acne Dermatoendocrinol. 2009 May;1(3):162-9. doi: 10.4161/derm.1.3.9364.
5 The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004 May;75(5):464-75.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.